Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

redpharm drug, inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 250 mg - 1.1 skin and skin structure infections ciprofloxacin tablets, usp are indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin­ susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. 1.2 bone and joint infections ciprofloxacin tablets, usp are indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. 1.3 complicated intra-abdominal infections ciprofloxacin tablets, usp are indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 500 mg - ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration  for specific recommendations. urinary tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, serratia marcescens, proteus mirabilis, providencia rettgeri, morganella morganii, citrobacter diversus, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or enterococcus faecalis. acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus. chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or penicillin-suscept

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

aphena pharma solutions - new jersey, llc - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 500 mg - ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration  for specific recommendations. urinary tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, serratia marcescens, proteus mirabilis, providencia rettgeri, morganella morganii, citrobacter diversus, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or enterococcus faecalis. acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus. chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or penicillin-suscept

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

xspire pharma, llc - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 0.5 mg in 0.25 ml - ciprofloxacin otic solution is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of pseudomonas aeruginosa or staphylococcus aureus . ciprofloxacin otic solution is contraindicated in persons with a history of hypersensitivity to ciprofloxacin. pregnancy category c. reproduction studies have been performed in rats and mice using oral doses of up to 100 mg/kg and intravenous (iv) doses up to 30 mg/kg and have revealed no evidence of harm to the fetus as a result of ciprofloxacin. in rabbits, ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturbances resulting in maternal weight loss and an increased incidence of abortion, but no teratogenicity was observed at either dose. after intravenous administration of doses up to 20 mg/kg, no maternal toxicity was produced in the rabbit, and no embryotoxicity or teratogenicity was observed. animal reproduction studies have not been conducted with ciprofloxacin otic solution. no adequate and well-controlled studies have been performed in pregnant women. caution should be exercised when ciprofloxacin otic solution is used by a pregnant woman. ciprofloxacin is excreted in human milk with systemic use. it is not known whether ciprofloxacin is excreted in human milk following otic use. because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. the safety and effectiveness of ciprofloxacin otic solution in infants below one year of age have not been established. the efficacy of ciprofloxacin otic solution in treating otitis externa in pediatric patients one year or older has been demonstrated in controlled clinical trials (see section 14 clinical studies). there is no evidence that the otic administration of quinolones has any effect on weight bearing joints, even though systemic administration of some quinolones has been shown to cause arthropathy in immature animals. no overall differences in safety and effectiveness have been observed between elderly and younger patients.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

depomed, inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride 500 mg - proquin xr is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of the designated microorganisms listed below. proquin xr is not interchangeable with other ciprofloxacin extended-release or immediate release oral formulations. see dosage and administration for specific recommendations. uncomplicated urinary tract infections (acute cystitis) caused by escherichia coli and klebsiella pneumoniae . the safety and efficacy of proquin xr in treating pyelonephritis, complicated urinary tract infections, and infections other than uncomplicated urinary tract infections have not been demonstrated. alternative therapy should be considered for patients who remain symptomatic or develop fever and back pain while on treatment with proquin xr. to reduce the development of drug-resistant bacteria and maintain the effectiveness of proquin xr and other antibacterial drugs, proquin xr should only be used to treat uncomplicated urinary tract infections tha

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

a-s medication solutions - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 250 mg - ciprofloxacin tablets are indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin­ susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin tablets are indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin tablets are indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin tablets are indicated in adult patients for treatment of infectious diarrhea caused by escherichia coli ( enterotoxigenic isol

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

henry schein inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 3 mg in 1 ml - ciprofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: *efficacy for this organism was studied in fewer than 10 infections. a history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. a history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 3 mg in 1 ml - ciprofloxacin ophthalmic solution, usp is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: a history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. a history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

remedyrepack inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 3.5 mg in 1 ml - ciprofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: corneal ulcers: pseudomonas aeruginosa serratia marcescens * staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae streptococcus (viridans group) * conjunctivitis: haemophilus influenzae staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae * efficacy for this organism was studied in fewer than 10 infections. a history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. a history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

unit dose services - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 3.5 mg in 1 ml - ciprofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: corneal ulcers: pseudomonas aeruginosa serratia marcescens * staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae streptococcus (viridans group) * conjunctivitis: haemophilus influenzae staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae * efficacy for this organism was studied in fewer than 10 infections. a history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. a history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin.